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Abstract
Purpose The research goal is to develop dietary strategies to help address the growing incidence of inflammatory bowel 
diseases (IBD). This study has investigated the effectiveness of green banana resistant starch (GBRS) and probiotic Bacillus 
coagulans MTCC5856 spores for the amelioration of dextran-sulfate sodium (DSS)-induced colitis in mice.
Methods Eight-week-old C57BL/6 mice were fed standard rodent chow diet supplemented with either B. coagulans, GBRS 
or its synbiotic combination. After 7 days supplementation, colitis was induced by adding 2% DSS in drinking water for 
7 days while continuing the supplemented diets. Animal health was monitored and after 14 days all animals were sacrificed 
to measure the biochemical and histochemical changes associated with each supplement type.
Results The disease activity index and histological damage score for DSS-control mice (6.1, 17.1, respectively) were sig-
nificantly higher (p < 0.0001) than the healthy mice. Synbiotic supplementation alleviated these markers (− 67%, − 94% 
respectively) more adequately than B. coagulans (− 52%, − 58% respectively) or GBRS (− 57%, − 26%, respectively) alone. 
Compared to DSS-control synbiotic supplementation significantly (p < 0.0001) maintained expressions of tight junction 
proteins. Moreover, synbiotic effects accounted for ~ 40% suppression of IL-1β and ~ 29% increase in IL-10 levels in serum 
while also reducing C-reactive protein (− 37%) compared to that of the DSS-control. While, B. coagulans alone could not 
induce additional levels of short-chain fatty acid (SCFA) production beyond the caecum, the synbiotic combination with 
GBRS resulted in substantial increased SCFA levels across the whole length of the colon.
Conclusion The synbiotic supplementation with B. coagulans and GBRS ameliorated the overall inflammatory status of the 
experimental IBD model via synergistic functioning. This supports researching its application in mitigating inflammation 
in human IBD.
Keywords Synbiotic · Prebiotic · Probiotic · Inflammatory bowel diseases · Bacillus spores · Green banana · Resistant 
starch · Mucosal barrier · Short-chain fatty acids
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0039 4-020-02200 -9) contains 
supplementary material, which is available to authorized users.
 * Tanvi Shinde 
 tanvi.shinde@utas.edu.au
 * Roger Stanley 
 roger.stanley@utas.edu.au
1 Centre for Food Safety and Innovation, Tasmanian Institute 
of Agriculture, University of Tasmania, Launceston, 
TAS 7250, Australia
2 School of Health Sciences, College of Health and Medicine, 
University of Tasmania, Launceston, TAS 7250, Australia
3 Centre for Human Psychopharmacology, Swinburne 
University of Technology, Hawthorn, VIC, Australia
4 Health and Biosecurity, Commonwealth Scientific 
and Industrial Research Organization (CSIRO), Gate 13 
Kintore Avenue, Adelaide, SA 5000, Australia
5 Land and Water, Commonwealth Scientific and Industrial 
Research Organization (CSIRO), Ecosciences Precinct, 
Dutton Park, QLD 4102, Australia
 European Journal of Nutrition
1 3
Introduction
The full pathogenesis of inflammatory bowel diseases 
(IBD), including Crohn’s disease (CD) and ulcerative 
colitis (UC), still remains unclear. Emerging evidence 
substantiates the role of interactions between genetic, 
environmental and immunological factors. Perturbations in 
the composition of the gut microflora (dysbiosis) are also 
associated with the occurrence of IBD [1–3]. As diet is a 
major factor influencing the enteric microflora, numerous 
research projects have, therefore, considered the role of 
specific nutrients in the development of IBD. The Western 
diet, characterised by low intake of dietary fibre, has been 
linked with increased risk of IBD in several studies [4]. It 
is also implicated in leading to gut dysbiosis that further 
aggravates gut inflammation. In this regard, prebiotic die-
tary fibres and probiotics are considered as critical compo-
nents of dietary improvements in the context of IBD. Both 
are bioactive agents that function to suppress inflammation 
via a number of proposed mechanisms [5–7]. Hence, vari-
ous probiotic and prebiotic agents are being increasingly 
explored to treat or prevent IBD in humans [7–9].
A number of factors influence the beneficial effects of 
probiotics. Their survival in delivery formats, including 
functional foods, is required. They must also survive dur-
ing gastric transit to exert health effects of the live organ-
ism [10]. In this context, Bacillus species are a growing 
research focus due to the ability of their heat-stable spores 
to survive gastric transit, harsh manufacturing and stor-
age temperatures and delivery formats that potentially 
involve hot foods [11, 12]. Furthermore, Bacillus strains 
are known to exert therapeutic effects owing to their ability 
to induce immune responses and to produce antimicrobial 
peptides that help mitigate inflammation [12]. Bacillus 
coagulans MTCC 5856 spores, specifically, have been 
shown to survive during adverse processing and storage 
conditions of functional foods [13], survive gastric transit, 
induce significant immunomodulatory effects in vitro [14] 
and exhibit beneficial effects in therapeutic management 
of clinical diarrhea [15].
An additional factor that may influence the beneficial 
effects of probiotics is their ability to generate fermenta-
tion products that influence the composition of the gut 
microbiome. This, in turn, can potentially improve the 
health of the host. Bacteriocins and organic acids are two 
possible antimicrobial products that can be produced by 
probiotics to influence and stabilize the gut microbiome 
[16, 17]. Other intermediate metabolites, including short-
chain fatty acids (SCFAs) produced as a consequence of 
bacterial fermentation of prebiotics in the gut, have been 
affirmed to exert beneficial effects on the host [6, 18]. 
The probiotic effect could, therefore, be potentiated by 
co-supplementation with prebiotic dietary fibres that can 
be metabolised and fermented by the administered pro-
biotic, as well as by beneficial microflora in the gut. The 
resulting production of metabolites can direct the shift of 
immune markers from pro-inflammatory to anti-inflam-
matory phenotype [19]. This combination of probiotic 
and prebiotic factors can be referred to as synbiotic. The 
approach potentially offers greater success of colonisa-
tion and survivability of beneficial bacteria owing to the 
greater effects that can be achieved compared to using 
either probiotics or prebiotics alone [20]. B. coagulans 
MTCC5856 is known to ferment variety of plant fibres 
[21–23]. It is, therefore, a candidate probiotic for synbiotic 
combination with plant prebiotic fibres.
Resistant starch (RS) is a plant prebiotic classified as 
a type of dietary fibre [24]. RS is defined as the sum of 
starch and the degradation products of starch that, on aver-
age, reaches the large intestine of healthy adult humans. 
Numerous clinical studies have successfully demonstrated 
the beneficial effects of RS on colonic health [24, 25]. Dried 
green banana (GB), ground to a flour, is a high volume nat-
ural food source of RS. It has been demonstrated to pre-
vent intestinal inflammation [26] and modulate oxidative 
stress [27] in animal models of colitis. It can also impart 
anti-diarrhoeal effects in children [28, 29]. GB flour is also 
being increasingly incorporated in food products to avoid 
gluten and provide food functionality such as stabilising 
emulsions [30–32]. Therefore, the combination of GB and 
B. coagulans could be used to create synbiotic functional 
foods targeted towards improving gut health. An effective 
combination would be of high interest for health food appli-
cations such as for mitigating inflammation in IBD patients. 
However improved knowledge on possible health effects, 
dosage response and mechanisms is needed to support such 
developments.
This study aimed to investigate the efficacy of pre-condi-
tioning the gut, using a diet supplemented with B. coagulans 
spores and GBRS, on ameliorating the severity of colitis 
in mice. By feeding the ingredients both individually and 
in combination, knowledge can be gained on the extent of 
synergistic interactions and the underlying mechanisms that 
generate the health effects.
Materials and methods
Probiotic bacteria and prebiotic dietary fibre
LactoSpore® containing probiotic strain B. coagulans 
MTCC 5856 (6 × 109 spores/g) was produced by Sami 
Labs Limited (Bangalore, India) and supplied by Sabinsa 
Corporation (Australia). Prebiotic green banana resistant 
starch (GBRS) flour (dietary fibre content—50%) was 
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supplied by Natural Evolution™, Australia. It is a product 
made by low-temperature drying of Musa acuminata cv 
Lady Finger. The nutritional composition of the GBRS is 
detailed in Supplementary Table 1.
Animals
Fifty C57BL/6J (7-week old) mice of both sexes of aver-
age weight 19 ± 1 g were obtained from the University of 
Tasmania animal breeding facility. They were housed in 
a temperature-controlled environment with a 12-h day/
night light cycle. Following an initial acclimation period 
of 7 days, the individual body weights were assessed daily 
during the experimental trial. All mice had ad libitum 
access to radiation-sterilised rodent feed pellets (Baras-
toc Rat and Mouse, Ridley AgProducts, Australia) and 
autoclaved tap water for drinking during experiments. All 
animal experiments were approved by the Animal Ethics 
Committee of the University of Tasmania (ethics approval 
number: A0015840) and conducted in accordance with 
the Australian Code of Practice for Care and Use of Ani-
mals for Scientific Purposes (8th Edition, 2013). All 
efforts were made to minimize animals’ suffering and to 
reduce the number of animals used.
Study design and treatments
Following 1 week of acclimation, mice at 8 weeks of age 
were randomly allocated into the following 5 groups (n = 10 
per group): (1) Healthy Control (HC), (2) DSS-control, 
(3) Probiotic B. coagulans MTCC 5856 (B. coagulans), 
(4) Prebiotic green banana resistant starch (GBRS) and 
(5) synbiotic B. coagulans and GBRS combination. The 
experimental design of the mice feeding trial is illustrated 
in Fig. 1. Mice in HC and DSS-control groups received 4 g 
chow mash (standard rodent chow pellet blended with water 
to form a mash and served to mice in 30 mm petri dishes 
placed in the cages). The standard rodent chow contained 
DF content of 3.2% crude fibre and 10.4% Neutral Detergent 
fibre as detailed in Supplementary Table 2. The B. coag-
ulans group received 4 g chow mash supplemented with 
probiotic B. coagulans MTCC 5856 spores (2 × 109 CFU/
day/mouse). The GBRS group received 4 g chow mash 
supplemented with GBRS (400 mg/day/mouse). The syn-
biotic group received 4 g chow each supplemented with B. 
coagulans MTCC 5856 spores (2 × 109 CFU/day/mouse) and 
GBRS (400 mg/day/mouse). The chow mash was prepared 
fresh each day. The mice were single-caged throughout the 
experiment to measure the defined daily intake of respective 
treatments from prepared chow mash. The mice were fed 
these treatments for 14 days. Colitis was induced during the 
last 7 days of the experimental period by administering 2% 
B. coagulans
Probiotic-supplemented
Chow
(14 days)
H2O + 2% DSS
(last 7 days)
B. coagulans
Spores
Normal H2O
(first 7 days)
H2O + 2% DSS
(last 7 days)
Normal H2O
(first 7 days)
Synbiotic
Synbiotic-supplemented
Chow
(14 days)
B. coagulans
Spores
DSS-Control
Unsupplemented
Chow
(14 days)
H2O + 2% DSS
(last 7 days)Normal H2O(first 7 days)
Analysis
• Disease activity index
• Macroscopic parameters
• Colonic histological scoring
• Immuno-histochemical
analysis of colonic tight
junction proteins
• Alcian blue mucus staining
• Analysis of colonic and
serum immune profile:
cytokines, iNOS and CRP
levels
• Faecal metabolomic profile
• Caecal, mucosal-associated
and faecal SCFA profile
Healthy Control
Unsupplemented
Chow
(14 days)
Normal H2O
(14 days)
GBRS
Prebiotic-supplemented
Chow
(14 days)
H2O + 2% DSS
(last 7 days)
Normal H2O
(first 7 days)
Green banana
resistant starch
(GBRS) flour GBRS
Fig. 1  Experimental design of in vivo feeding trial to analyse prophy-
lactic efficacy of B. coagulans spores, GBRS and synbiotic in DSS-
induced acute colitis mice model. C57BL/6J mice (n = 10 per group) 
were fed chow supplemented with either B. coagulans spores, GBRS 
or their synbiotic combination for 14  days. Colitis was induced by 
administration of 2% DSS in drinking water for the last 7 days
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dextran sulfate sodium (DSS; MP Biomedicals, colitis grade 
average molecular weight: 36,000–50,000) in the drinking 
water of all groups except for non-colitic control mice which 
received normal drinking water. Mice were sacrificed on day 
15 by  CO2 asphyxiation.
Clinical scoring and histological analysis
A disease activity index (DAI) was determined daily in all 
mice by scoring for body weight, hemoccult reactivity, pres-
ence of gross blood and stool consistency during the week 
of DSS induction. DAI was determined by combining the 
scores from these three categories as described previously 
[19]. Faecal samples were collected on day 14 and stored 
at − 80 °C for metabolite analysis. After sacrificing the mice, 
the colons were dissected from the caecum to the anus as 
described previously [19]. Spleen weight, colon length, 
colon weight/body weight ratio were calculated as macro-
scopic markers of inflammation. The mucosal and caecal 
contents were collected by scraping with sterile pipette tips 
for SCFA and metabolite profiling and stored at − 80 °C. 
The colon was bisected longitudinally, and one half was 
prepared using the Swiss roll technique [33], whereas the 
remaining colonic tissue was dissected out, segregated into 
proximal colon (PC) and distal colon (DC) and snap-frozen 
for molecular analyses. Swiss rolls underwent 24 h fixation 
in 10% (v/v) neutral-buffered formalin. Swiss rolls were 
subsequently transferred to 70% ethanol prior to progres-
sive dehydration, clearing and infiltration with HistoPrep 
paraffin wax (Fisher Scientific, Philadelphia, PA, USA). 
Swiss rolls were then embedded in wax and 5 μm sections 
were cut using a rotary microtome. For histological analysis, 
proximal and distal colon tissue sections (n = 8 per group) 
were stained with haematoxylin and eosin stain (H and E; 
HD Scientific, Sydney, Australia). The slides were graded 
by assessors blinded to the experimental treatments for the 
severity of tissue damage at distal and proximal regions as 
described previously [19]. All images were captured on a 
Leica DM500 microscope using a Leica ICC50 W camera 
(Leica Microsystems, Wetzlar, Germany).
Alcian blue staining
DSS-induced alterations in goblet cells, and subsequent 
depletion in synthesis and secretion of mucin glycoprotein, 
were analysed by Alcian blue staining (ab150662 Alcian 
Blue, pH 2.5 (Mucin Stain), Abcam, Australia) following 
the manufacturer’s instructions. The staining intensity (IOD) 
was assessed using Image Pro Plus 7.0 (Media Cybernetics, 
Inc., Rockville, MD, USA) and used for comparison among 
groups [34].
Immunohistochemical detection of tight junction 
proteins
Immunohistochemical detection of epithelial tight junction 
(TJ) proteins: ZO-1, occludin and claudin-1 was performed 
using a Rabbit specific HRP/DAB (ABC) Detection IHC kit 
(ab64261, Abcam, Australia) following the manufacturer’s 
instructions and as previously described [19]. Antibodies 
anti-ZO-1 (NBP1-85046, Novus Biologicals, Australia, 
1:400); anti-occludin (NBP1-87402, Novus, 1:600) and anti-
claudin-1 (NBP1-77036, Novus, 1 μg/mL) were used for 
incubating the colonic sections overnight at 4 °C. Computer-
assisted image analysis was performed with a Leica DM500 
microscope (Leica Microsystems, Wetzlar, Germany), Leica 
ICC50 W camera (Leica Microsystems, Wetzlar, Germany), 
and Image Pro Plus 7.0 (Media Cybernetics, Inc., Rockville, 
MD, USA) software. The expression of tight junction (TJ) 
proteins: ZO-1, occludin and claudin-1 was blindly assessed 
by choosing random five fields on each slide (n = 4/group). 
Barrier TJ protein expressions and staining intensity in 
colonic epithelium were expressed as the percentage expres-
sion of a respective TJ protein.
Myeloperoxidase activity
The extent of the inflammatory cell invasion in the colon 
was examined by the assessment of myeloperoxidase (MPO) 
activity [35]. Weighed and snap-frozen PC and DC speci-
mens (n = 3) were analysed for MPO activity using a Mye-
loperoxidase Activity Assay kit (ab105136, colorimetric, 
 Abcam®, Cambridge, UK) following the manufacturer’s 
instructions. The values are expressed as MPO activity 
units/g tissue.
Tissue explant culture and cytokine measurements
PC (n = 3) and DC (n = 3) colon tissues of mice from each 
group were cut, weighed and washed with cold phosphate-
buffered saline (PBS) before transferring to a 12-well plate 
containing 0.5 mL/well of RPMI1640 culture medium (In 
Vitro Technologies Pty Ltd, Melbourne, Australia) sup-
plemented with 10% v/v foetal calf serum (Gibco, Life 
Technologies Pty Ltd, Melbourne, Australia), penicillin 
(100 mU/L), and streptomycin (100 mg/L) (Sigma-Aldrich 
Pty Ltd, Sydney, Australia) as described previously [36]. 
After 24 h of incubation, the supernatant was collected from 
each well, centrifuged and stored at − 80 °C until further 
analysis. Serum was collected from blood drawn by cardiac 
puncture at the end of the study for cytokine analysis.
The cytokine levels in colon tissue (n = 3) and serum 
(n = 3) were determined by immunoassay using a Bio-Plex 
Pro Mouse cytokine 23-plex kit (Bio-Rad #M60009RDPD, 
Bio-Rad Laboratories, Gladesville, NSW, Australia) 
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following the manufacturer’s instructions and concentrations 
analysed using a Bio-Plex 200 instrument (Bio-Rad) and 
Bioplex Manager software, version 6 (Bio-Rad Laborato-
ries) respectively [36]. For tissues, the cytokine levels were 
normalized by dividing the cytokine results (pg/mL) by the 
measured biopsy weight (g). The most significantly altered 
cytokines are presented as pg/g of tissue.
iNOS activity
The expression of inducible isoforms of nitric oxide syn-
thase (iNOS) in colonic epithelial cells in response to pro-
inflammatory stimuli [37] was determined in PC (n = 3) and 
DC (n = 3) specimens using a Nitric Oxide Synthase Activ-
ity Assay kit (ab211084, Fluorometric,  Abcam®, Cambridge, 
UK), following the previously described method [19]. The 
results are expressed as iNOS activity mU/mg.
Serum C‑reactive protein analysis
The levels of C-reactive protein (CRP) in serum from 
respective groups (n = 3 samples/group) were analysed 
using Mouse C-Reactive Protein/CRP Quantikine Elisa kit 
(MCRP00, R&D Systems, Australia) following the manu-
facturer’s instructions. The results are expressed as μg/mL.
Volatile SCFA analysis
The contents of colon (mucosal-associated) and caecum 
were collected by scraping with sterile pipette tips for 
SCFA profiling and stored at − 80 °C. GC–MS analysis 
of 100–150 mg fresh weight (stored at − 80 °C) of caecal, 
mucosal-associated and faecal samples (n = 5 per group) 
each was used for volatile SCFA profiling following the 
method described previously [19, 38]. The samples were pre-
pared and derivatized following the protocol developed by 
Furuhashi et al. [39] with some modifications. Briefly, cae-
cal, mucosal-associated and faecal samples of 100–150 mg 
fresh weight (stored at − 80 °C) were weighed to ± 0.1 mg 
accuracy. These samples were added to a sterile 1.5 mL 
bead-beating tube (NAVY Rino Lysis tubes, Next Advance, 
Troy, NY, USA). A 1.0 mL aliquot isobutanol (10% MilliQ 
water), (LC–MS grade, Merck, Castle Hill, NSW, Australia) 
was added to each sample, followed by two 30 s, 4000 rpm 
homogenization pulses sandwiched between a 20-s pause 
interval (Precellys Evolution Homogenizer, Bertin Instru-
ments, Montigny-le-Bretonneux, France). The samples were 
subsequently centrifuged at 16,000×g for 6 min.
The supernatant (675 µL) was transferred to a clean 
round-bottomed 2 mL centrifuge tube (Eppendorf South 
Pacific Pty. Ltd., Macquarie Park, NSW, Australia) and 
NaOH (20 mM, 125 µL, Merck Pty Ltd., Castle Hill, NSW, 
Australia) and chloroform (400 µL, LC–MS grade, Merck 
Pty Ltd.,) were added. The samples were briefly vortexed 
and centrifuged at 16,000g for 3 min. The aqueous phase 
(upper layer, 400 µL) was transferred to a new clean round-
bottomed 2 mL centrifuge tube (Eppendorf South Pacific 
Pty. Ltd., Macquarie Park, NSW, Australia) containing a 
boiling chip (Sigma Aldrich, Castle Hill, NSW, Australia). 
Pyridine (100 µL), isobutanol (80 µL) (both LC–MS grade, 
Sigma Aldrich, Castle Hill, NSW, Australia), and MilliQ 
(Millipore Corporation) water (70 µL) were added and the 
samples were subjected to gentle hand vortexing (swirling 
action) followed by the addition of 50 µL isobutyl chloro-
formate (98% purity, Sigma Aldrich, Castle Hill, NSW, Aus-
tralia). The tube was kept opened to release any generated 
gases and was allowed to stand for about 1 min. Hexane 
(150 µL, LC–MS grade, Sigma Aldrich, Castle Hill, NSW, 
Australia) was then added to each tube, which was then 
capped and vortexed prior to centrifugation at 15,700×g for 
4 min. The upper phase (100 µL) was subsequently trans-
ferred to clean gas chromatography (GC) autosampler vial 
fitted with silanized low volume glass inserts; Malathion 
(1 µL, equivalent to 2.5 µg dry weight) was added as an 
internal standard.
The GC–MS analysis was performed on an Agilent 
6890B GC oven coupled to a 5977B mass spectrometer 
(MS) detector (Agilent Technologies, Mulgrave, VIC, Aus-
tralia) fitted with an MPS autosampler (Gerstel GmbH & 
Co.KG, Mülheim an der Ruhr, Germany). The GC oven was 
fitted with two 15 m HP‐5MS columns (0.25 mm ID and 
0.25 µm film thickness; 19091S-431 UI (Ultra Inert), Agi-
lent Technologies, VIC, Australia) coupled to each other 
through a purged ultimate union (PUU) for the use of post-
run backflushing. The sample (1.0 µL) was introduced via a 
multimode inlet (MMI) operated in split mode (1:20). The 
column was maintained at 40 °C for 5 min, followed by an 
increase to 250 °C at a rate of 10 °C/min. This was followed 
by a second increment to 310 °C at a rate of 60 °C/min. The 
column was held at 310 °C for 1 min. The mass spectrom-
eter was kept in extractor ion mode (EI mode) at 70 eV. 
The GC–MS ion source temperature and transfer line were 
kept at 250 °C and 280 °C, respectively. Detector voltage 
was kept at 1054 V. The MS detector was turned off for the 
first 3 min and, at 4.0–4.8 min and 12.5- to 13.2-min time 
windows until the excess derivatization reagent (chlorofor-
mate/hexane solvents) were eluted from the column. This 
ensured that the source filament was not saturated and dam-
aged. The scan range was kept in the range of m/z 35–350 
(35–350 Da). Data acquisition and spectral analysis were 
performed as described in a previous study [38] and quali-
tative identification of metabolites was performed accord-
ing to the Metabolomics Standard Initiative (MSI) chemical 
analysis workgroup [40] using standard GC–MS reference 
metabolite libraries (NIST 17, and an in-house CF-based 
metabolomics library developed after Smart et al. [41] with 
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the use of Kovats retention indices based on a reference 
n-alkane standard (C8-C40 Alkanes Calibration Standard, 
Sigma-Aldrich, Castle Hill, NSW, Australia).
Metabolomic analysis
In addition, untargeted GC–MS metabolomic profiling 
of faecal samples (n = 5 per group) was performed using 
GC–MS analysis as described previously [19, 38]. The sam-
ples were subjected to derivatisation to increase volatility 
before subjecting to GC–MS analysis. Briefly, the samples 
(n = 5, weight = 40 mg) were freeze-dried and suspended in 
1 mL methanol (LC–MS grade, Merck, Castle Hill, NSW, 
Australia), supplemented with 10 µg/mL adonitol (Analyti-
cal grade, Sigma Aldrich, Castle Hill, NSW, Australia) as 
an internal standard in a sterile 2 mL bead-beating tube. 
The samples were homogenized by bead beating for 30 s 
and then centrifuged at 570 g/4 °C for 15 min. The super-
natant (50 µL) was transferred to a fresh centrifuge tube 
(1.5 mL) and dried in a vacuum evaporator centrifuge (Lab-
Gear, Brisbane, QLD, Australia) at 35 °C. Methoxyamine-
HCl (20 mg/mL in Pyridine) (both, Analytical grade, Sigma 
Aldrich, Castle Hill, NSW, Australia) was added (40 µL) and 
samples were incubated at 30 °C/1400 rpm (ThermoMixer 
C, Eppendorf, Hamburg, Germany) for 90 min. This was fol-
lowed by sialylation with 70 µL BSTFA at 37 °C/1400 rpm 
for 30 min. Pre-derivatized 13C-stearic acid (10 µg/mL) was 
added (1 µL) as the QA/QC internal standard. The mixture 
was briefly vortexed and centrifuged at 15,700g for 5 min. 
The aliquot was transferred to vials for GC–MS analysis.
The GC–MS analysis was performed on an Agilent 
6890B gas chromatograph (GC) oven coupled to a 5977B 
mass spectrometer (MS) detector (Agilent Technologies, 
Mulgrave, VIC, Australia) fitted with an MPS autosampler 
(Gerstel GmbH & Co. KG, Deutschland, Germany). The 
GC–MS conditions were as stated previously [42–44]. Data 
acquisition and spectral analysis were performed using the 
Qualitative Analysis software (Version B.08.00) of Mass-
Hunter Workstation (Agilent Technologies). Qualitative 
identification of the compounds was performed according 
to the Metabolomics Standard Initiative (MSI) chemical 
analysis workgroup [40] using standard GC–MS reference 
metabolite libraries (NIST 17, Fiehn Metabolomics RTL 
Library (G166766A, Agilent Technologies) and the Golm 
database) and with the use of Kovats retention indices based 
on a reference n-alkane standard (C8-C40 Alkanes Calibra-
tion Standard, Sigma-Aldrich, Castle Hill, NSW, Australia). 
For peak integration, a five-point detection filtering (default 
settings) was set with a start threshold of 0.2 and a stop 
threshold of 0.0 for 10 scans per sample. Procedural blanks 
(n = 7) were analysed randomly throughout the sequence 
batch. The obtained data were processed on the Quantitative 
Analysis software of MassHunter Workstation and exported 
as a Microsoft Excel output file for statistical analysis.
GC–MS data imported to Microsoft Excel platform was 
normalized with respect to the internal standard adonitol 
(relative standard deviation = 11.257%). The normalized 
data was further log-transformed and auto-scaled (mean-
centred) before statistical analysis [45]. For analysis of 
metabolome variations, partial least squares-discriminant 
analysis (PLS-DA) and orthogonal (O) PLS-DA were used. 
Because PLS-DA can overfit data, we used 1000 permuta-
tions to validate these models. The OPLS-DA was used to 
identify discrimination between metabolites contributing to 
classification as previously described [38].
Statistical analysis
The samples in the study were randomly chosen for 
all the analyses to avoid bias. All data are presented as 
means ± standard error of the mean (SEM). The statistical 
analysis was performed with the use of GraphPad Prism 
Software (Version 7.0, San Diego, CA, USA). The data were 
evaluated using One-way analysis of variance (ANOVA) fol-
lowed by Tukey’s post hoc test to determine statistical differ-
ences between the groups against the DSS-control samples. 
For the analysis of DAI and body weight changes during the 
experimental period, two-way ANOVA followed by Tukey’s 
post hoc test was used, setting treatment and the time as the 
variables. A p value of < 0.05 was considered significant. 
A MetaboAnalyst (Version 4.0) data annotation approach 
and Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
Pathway Database were used for the hierarchical clustering 
analysis and significance analysis for microarrays (SAM), 
along with the variable importance of projection (VIP) [46]. 
The SAM and VIP methods are well-established statistical 
methods for metabolites and were used to select the most 
discriminant and interesting biomarkers [47].
Results
Effects of B. coagulans, GBRS and synbiotic 
supplementation on clinical manifestations 
and macroscopic inflammatory markers
DSS-induction resulted in a progressive increase in colonic 
inflammation as demonstrated by severe body weight loss 
and high DAI (Fig. 2a, b). However, supplementation of B. 
coagulans, GBRS and synbiotic treatments started 7 days 
prior to DSS-induction, attenuated the impact of the DSS 
damage and boosted the recovery of the treated animals. This 
is evidenced by the significant reduction in body weight loss 
and by lower incidences of diarrheic/bloody faeces, resulting 
in lower DAI values throughout the experiment in the treated 
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Fig. 2  Effect of B. coagulans spores, GBRS and synbiotic on clini-
cal manifestations in DSS-induced colitis mice. a Disease activ-
ity index (DAI), b % body weight change. Statistical significance 
among groups evaluated by two-way repeated-measures analysis of 
variance (ANOVA) followed by Tukey’s test. *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001 vs. DSS-control group and data 
expressed as mean ± SEM (n = 10 per group). Colon weight/body 
weight ratio (c), spleen weight (d), colon length (e) and macroscopic 
appearance of colon (f). Data expressed as mean ± SEM (n = 10 per 
group), evaluated by one-way ANOVA followed by Tukey’s test. NS 
non-significant
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groups when compared to the untreated DSS-control group. 
At the end of the experiment on day 8, DAI was significantly 
(p < 0.0001) higher for the DSS-control (6.1 ± 0.5) compared 
to B. coagulans (2.9 ± 0.4, 52% reduction), GBRS (2.6 ± 0.4, 
57% reduction) and synbiotic (2 ± 0.2, 67% reduction) mice 
(Fig. 2b). Moreover, probiotic, prebiotic and synbiotic sup-
plementation significantly (p < 0.0001) reduced the loss of 
body weight compared to that of DSS-control group starting 
from day 6.
The macroscopic evaluation of colonic segments 
affirmed the remedial effects of all three treatments used in 
our study. This was indicated by a substantial reduction in 
colon weight/body weight ratio (B. coagulans, 7.70 ± 0.2; 
GBRS, 9.32 ± 0.3 and synbiotic, 8.3 2 ± 0.3 mg/g) compared 
with the DSS-control group (11.16 ± 0.2 mg/g) (Fig. 2c). 
The relative spleen weights of the DSS-control mice were 
also markedly higher (0.08 ± 0.004 g) than that of GBRS 
(0.063 ± 0.002  g) and synbiotic (0.062 ± 0.003  g) mice 
(Fig. 2d). B. coagulans had no effect on spleen weight reduc-
tion (0.068 ± 0.004 g). B. coagulans (7.80 ± 0.3 cm), GBRS 
(7.91 ± 0.2 cm) and synbiotic (8.09 ± 0.2 cm) supplementa-
tion effectively prevented the colon shortening compared 
with the DSS-control group (6.80 ± 0.3 cm) (Fig. 2e, f).
Effects of B. coagulans, GBRS and synbiotic 
supplementation on histological alterations in colon
Histological (H&E staining) examination of proximal colon 
(PC) and distal colon (DC) sections of DSS-induced mice 
displayed histological damage with erosion or destruction of 
epithelium, crypt distortion, depletion of goblet cells, sub-
mucosal oedema and inflammatory cellular infiltration in 
the colon, mostly affecting the distal section (Fig. 3a). While 
HC showed no signs of histological colon damage (score 
0), DSS resulted in a cumulative damage score of 9.38 ± 0.8 
for PC and 17.1 ± 0.4 for DC (Fig. 3b). Supplementation 
with synbiotic and B. coagulans induced protection against 
the damage, as evidenced by substantial retention of colonic 
structure, protection of crypts and goblet cells, and reduced 
infiltration of inflammatory cells. This resulted in a signifi-
cant overall reduction of cumulative histological scores of 
DC (8.8 ± 0.5, 10.8 ± 1.0 for synbiotic and B. coagulans 
respectively). GBRS provided a partial, but significant, pro-
tection with a histological score of 13.6 ± 0.7. In contrast, 
histology scores for PC demonstrated no statistically signifi-
cant protection by the three treatments. MPO assay, however, 
showed a substantial reduction in neutrophil infiltration in 
PC by synbiotic and B. coagulans compared with that of 
the DSS-colitic group. In DC, all three supplementations 
were successful in reducing the inflammatory cell infiltrate, 
as determined by decreased MPO activity (Fig. 3c), with B. 
coagulans and synbiotic being more effective than GBRS.
Effects of B. coagulans, GBRS and synbiotic 
supplementation on goblet cells and colonic tight 
junction barrier
Staining with Alcian blue was performed to examine the 
effect of supplementation on DSS-induced alterations in the 
mucus secretion by goblet cells. Significantly high mucus 
staining with Alcian blue was detected in colon sections of 
mice supplemented with B. coagulans and synbiotic, with 
moderate staining of GBRS mucus suggesting induction of 
high secretion levels of mucus in DSS-challenged mice that 
received supplementations (Fig. 4). In comparison, in DSS-
control colon sections, the goblet cells were almost entirely 
destroyed.
Immunohistochemical analysis was performed to inves-
tigate the impact of supplementation on the assembly of the 
TJs and the integrity of the intestinal barrier. The presence 
of the TJ proteins-ZO-1, occludin and claudin-1 were ana-
lysed for in the colonic tissue sections (Fig. 5). In HC sec-
tions, ZO-1 staining (Fig. 5a) was more intense in the apical 
tight junction complex, both at the surface and in the crypts. 
Occludin (Fig. 5b) and claudin-1 (Fig. 5c) proteins stained 
more strongly at the basolateral membrane of the crypts, 
and also showed their presence at the crypt surface. In DSS-
control sections however, such signals were weak or totally 
absent, in line with previous reports [48, 49], indicating a 
low percentage of TJ protein expression. B. coagulans and 
synbiotic supplementation, however, effectively maintained 
the basolateral and partial apical staining of ZO-1, occludin 
and claudin-1 in DSS-induced mice. GBRS only displayed 
partial maintenance of ZO-1 staining, although the effect 
was less noticeable for occludin and claudin-1. In contrast, 
synbiotic supplementation significantly maintained the TJ 
patterns similar to that of HC sections, indicating a high 
level of protection of the integrity of the epithelium.
Immunomodulatory effects of B. coagulans, GBRS 
and synbiotic supplementation on immune markers
Bacillus coagulans, GBRS and synbiotic supplementation 
improved the altered immune responses induced by DSS 
thus showing their immunomodulatory and anti-inflamma-
tory effects (Fig. 6). In comparison with the DSS-control 
group, all three treatments substantially reduced the tested 
Fig. 3  Effect of B. coagulans spores, GBRS and synbiotic treat-
ments on DSS-induced colonic tissue injury. a Histological images 
of proximal and distal colonic tissues stained with hematoxylin and 
eosin at × 20 for each experimental group. b Histological score cal-
culated after microscopic analyses of proximal and distal sections of 
the colon. c Myeloperoxidase (MPO) activity in colonic tissues was 
determined by colorimetric assay. Results, expressed as mean ± SEM 
(n = 8 per group), were evaluated by one-way ANOVA followed by 
Tukey’s test (*p < 0.05, **p < 0.01, ****p < 0.0001)
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pro-inflammatory cytokine levels of IL-1α, IL-1β, IL-6, 
IL-12, TNF-α, IFN-γ in PC and DC segments. However, no 
significant effect of supplementations was noted on levels 
of the other cytokines (Supplementary Fig. 1). Supplemen-
tation with B. coagulans alone and with synbiotic proved 
effective in reducing the levels of all the cytokines tested 
Fig. 4  Effect of B. coagulans spores, GBRS and synbiotic on goblet 
cells. The paraffin embedded sections were stained with Alcian Blue 
to detect changes in goblet cells and in production of mucus in dis-
tal colonic tissue in each experimental group (× 40). Staining inten-
sity (IOD) of respective group is illustrated in the graph. Results 
expressed as mean ± SEM (n = 4 per group), evaluated by one-way 
ANOVA followed by Tukey’s test (*p < 0.05, ***p < 0.001)
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in comparison with that of the DSS-control mice. Relative 
to that of DSS-control, there was a pronounced reduction 
in increases of IL-1β (-60%), IL-6 (-62%), TNF-α (-66%) 
and IFN-γ (-73%) levels by B. coagulans supplementation in 
comparison with that of GBRS (IL-1β: − 36%, IL-6: − 35%, 
TNF-α: − 46%, IFN-γ: − 57%). However, GBRS had no 
significant effect on the levels of IL-1α, IL-12 and TNF-α 
in DC. The synbiotic supplementation proved effective in 
reducing the levels of all pro-inflammatory cytokines, in 
comparison with elevated cytokine levels in the DSS-con-
trol. Relative to that of DSS-control, the synbiotic supple-
mentation compared with those of the GBRS supplementa-
tion also displayed greater reduction in the levels of IL-6 
(− 78%, p = 0.012), IL-12 (− 56%, p = 0.003) and IFN-γ 
(− 71%, p = 0.526) as well as greater suppression in the 
level of IL-1β (− 75%, p = 0.181) compared to that of B. 
coagulans.
Serum cytokines indicative of immunomodulatory effects 
also followed a similar trend (Fig. 6g–i). Synbiotic signifi-
cantly decreased the pro-inflammatory serum cytokine levels 
of IL-1β (50.1 ± 4.6 pg/mL) and IL-12 (146.4 ± 7.4 pg/mL) 
while, concomitantly increasing anti-inflammatory IL-10 
(181.7 ± 6.1 pg/mL) levels compared with the DSS-control 
group (IL-1β: 82.8 ± 4.1 pg/mL, IL-12: 246.6 ± 6.0 pg/mL 
and IL-10: 140.5 ± 6.5 pg/mL). While, B. coagulans and 
GBRS supplementations alone were not effective in reducing 
increased serum IL-1β (66.1 ± 7.0 and 59.38 ± 5.0 pg/mL, 
respectively), substantial reduction in IL-12 (179.3 ± 12.3 
and 169.5 ± 11.1 pg/mL, respectively) was achieved relative 
to that of the DSS-control. No statistically significant effect 
was observed for other serum cytokines (Supplementary 
Fig. 1). DSS-induction elevated iNOS activity in both PC 
and DC in response to the pro-inflammatory stimulus, in line 
with the previous report [37]. Synbiotic and B. coagulans 
lowered the iNOS activity significantly, while GBRS had no 
effect. Moreover, compared to the high CRP levels in DSS-
control (14.81 ± 0.6 μg/mL), B. coagulans (10.31 ± 0.3 μg/
mL), GBRS (10.61 ± 0.7 μg/mL) and synbiotic (9.4 ± 0.2 μg/
mL) all reduced the serum CRP levels. Synbiotic and B. 
coagulans supplementations induced normalisation of CRP 
levels and were statistically similar to that of HC levels 
(8.3 ± 0.5 μg/mL). These observations indicated that a com-
bination of probiotic spore and prebiotic GBRS resulted in 
an effective level of immunomodulatory activity.
Effects of B. coagulans, GBRS, and synbiotic 
supplementation on alteration of faecal metabolic 
profile
Faecal samples were analysed by GC–MS platform to gain 
an untargeted overview of alterations in dominant gut metab-
olites induced by B. coagulans, GBRS and synbiotic sup-
plementations in DSS-treated mice. The analysis detected 
a total of 61 metabolites belonging to different functional 
groups such as sugars, amino acids, volatile fatty acids and 
biogenic amines. A supervised partial least squares-discri-
minant analysis (PLS-DA) was performed to evaluate meta-
bolic phenotyping of each experimental group (Fig. 7a). The 
remoteness between the samples from HC and DSS-control 
indicates a clear distinction in metabolic patterns between 
the groups. Among the supplemented groups, samples from 
B. coagulans and GBRS clusters overlapped with each other, 
and with that of HC, and partially with DSS-control. The 
synbiotic cluster showed a clear divergence relative to that 
of the DSS-control samples suggesting its potential to induce 
marked changes in the metabolic profile. The combination 
of PLS-DA (R2Y = 0.803 (p = 0.01), Q2 = 0.521), VIP scores 
(Fig. 7b) and SAM enabled the identification of potential 
biomarkers. The results showed 61 metabolites, with 28 
statistically significant compounds contributing to the clus-
tering. Their significance analysis for microarrays (SAM) 
scores fold changes and International Chemical Identifiers 
(InChI) and standard InChI hashes (InChIKey IDs) listed in 
Supplementary Table 3. Key metabolic markers making a 
significant contribution were identified by VIP analysis as 
displayed in Fig. 7b. Among these identified metabolites, 
substantial differences in the patterns between DSS-control 
and HC were particularly noted for allantoin, threitol, arabi-
tol, uracil, aspartic acid, palmitic acid, myristic acid, hypox-
anthine and 6-deoxy-d-glucose. Synbiotic supplementation 
generated a reduction in the metabolic alterations induced 
by DSS (Fig. 7b and Supplementary Table 3).
Effects of B. coagulans, GBRS and synbiotic 
supplementation on SCFA levels
DSS-induction lead to variation in SCFA production com-
pared to that of HC across the samples of intestinal contents 
collected from different colonic sites (caecal, mucosal-
associated and faecal) as depicted in Fig. 8. However, there 
were no statistically significant differences between the con-
centrations of acetate, propionate, valerate and succinate in 
the DSS-control and the HC mice, with the exception for 
butyrate levels in the caecum. Supplementation of mice with 
B. coagulans, GBRS and synbiotic induced significantly 
increased SCFA levels although they varied across differ-
ent sample types. Overall, the highest SCFA levels were 
detected in caecal contents followed by faecal and mucosal-
associated samples. Interestingly, B. coagulans alone was 
noted to increase the SCFA levels in the caecum while no 
effect was observed in SCFA levels in mucosal-associated 
or faecal samples except for propionate. However, synbiotic 
and GBRS were effective in elevating the levels of acetate, 
propionate and butyrate in the caecal and faecal contents 
compared to that of the DSS-control.
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Bacillus coagulans  (10.9 ± 0.8  μg/g), GBRS 
(11.2 ± 1.7 μg/g) and synbiotic (10.6 ± 1.1 μg/g) caused 
significant elevations in butyrate levels in the caecum com-
pared with that of DSS-control (2.45 ± 0.4 μg/g). GBRS 
(11.8 ± 2.0  μg/g) and synbiotic (10.9 ± 0.7  μg/g) were 
also noted to increase faecal butyrate levels compared to 
that of DSS-control (3.72 ± 1.0 μg/g), while B. coagulans 
(6.89 ± 1.2 μg/g) had no effect. GBRS and synbiotic also 
increased faecal valerate levels. Synbiotic supplementation 
lowered succinate levels although not statistically. Such 
alterations in SCFAs by synbiotic supplementation indicates 
the excellent potential of the bioactive ingredients in induc-
ing beneficial SCFA modulations.
Discussion
Application of dietary strategies to prevent the onset or 
reduce the severity of IBD is gaining momentum. The 
mechanisms that contribute to managing IBD appear to act 
through modulating cytokine responses, epithelial integ-
rity and gut microbiota [50, 51]. The results of the present 
study clearly indicated that pre-conditioning of the gut with 
synbiotic supplementation carrying probiotic and prebiotic 
components markedly reduced the symptoms and severity 
of DSS-induced colitis in the mouse model. The results sup-
ported the anti-inflammatory potentials of both the probiotic 
B. coagulans MTCC5856 and GBRS supplement ingredi-
ents. However, the effect was noted to be more profound 
with synbiotic supplementation, as illustrated by its ability 
to prevent the clinical manifestations, macroscopic, his-
tological, biochemical, metabolic and immune parameter 
changes in the DSS-induced colitic mice. Synergistic action 
between the two bioactive components could account for 
such enhanced beneficial effect.
The feeding of DSS-induced mice with B. coagulans, 
GBRS and synbiotic supplements significantly (p < 0.0001) 
lowered the DAI scores observed by the marked reduction in 
body weight loss and lower incidences of diarrheic/ bleeding 
faeces compared to that of DSS-control mice (Fig. 2). Addi-
tionally, the supplementations prevented spleen enlargement, 
increase in colon weight/body weight ratio and colon short-
ening. These macroscopic markers are directly associated 
with intestinal inflammation and disease severity in experi-
mental colitis models [35]. Green banana-supplemented 
diets [29] and B. coagulans spores [15] have each previously 
been shown to reduce clinical diarrheal episodes, in line 
with the observations on DDS-induced mice in the current 
study. The anti-diarrheic effect of GBRS could be due to its 
high RS content that, upon reaching the caecum/colon, is 
metabolized by bacteria to SCFAs [27]. These, in turn, stim-
ulate salt and water absorption, provide energy and induce 
a trophic effect on the colon [29]. Cooking banana (Musa 
acuminata) have been previously characterised for their high 
RS content and prebiotic properties [52]. High RS content 
(38% of the total DF content) of the GBRS flour from dip-
loid cultivars of M. acuminata “Lady Finger” bananas used 
in the current study could be accounted for the observed 
positive effects. The ability of B. coagulans to elicit the anti-
diarrheic effect could be via several proposed mechanisms 
that include suppression and binding of pathogenic bacteria, 
improvement of the epithelial barrier function and alteration 
of the immune activity of the host [15]. Synbiotic supple-
mentation that combines these effects should stimulate more 
profound efficacy outcomes against manifestations of IBD. 
This was supported by the observations in the current study.
Histological studies, not easily possible in human clini-
cal trials, also showed a potential synbiotic outcome. There 
was a marked preservation of the structure of the epithelium 
of the colon of synbiotic supplemented mice (Fig. 3a, b) 
compared to the DSS-control, as well as to the B. coagulans 
and GBRS supplementations alone. Synbiotic supplementa-
tion also showed marked protection to the colonic epithelial 
architecture by alleviating crypt disruption, loss of goblet 
cells, submucosal oedema and inflammatory infiltrates 
induced by DSS.
In other biomarkers of IBD activity related to mucosal 
integrity, synbiotic supplementation caused a significant 
reduction (p < 0.0001) in MPO activity (Fig. 3c) especially 
in the DC section compared to that of DSS-control. MPO 
activity may cause oxidative damage to host tissue and 
induce or perpetuate inflammation. MPO is an important 
diagnostic and prognostic tool in assessing IBD status [53]. 
The level of MPO activity is directly proportional to the 
neutrophil concentration and thus is an index of neutrophil 
infiltration and inflammation [49]. Neutrophil-myeloperox-
idase is an enzyme that catalyses the production of reactive 
oxygen species and is increased in the mucosa of patients 
with IBD [53]. This suggests that synbiotic supplementa-
tion had an anti-inflammatory effect that correlates to the 
histological evidence of protection.
Synbiotic supplementation in this study, followed in effi-
cacy by B. coagulans and GBRS alone, were also effec-
tive in protecting the TJ proteins (ZO-1, occludin and clau-
din-1) in DSS-induced mice (Fig. 5). Disruption of intestinal 
epithelial TJs, and impaired epithelial barrier function, is 
a prominent event in the pathogenesis of clinical colitis 
that further promotes dysregulated immune reactions, thus 
aggravating gut inflammation. TJs maintain the epithelial 
Fig. 5  Effects of B. coagulans spores, GBRS and synbiotic on expres-
sion of epithelial tight junction proteins. Immunohistochemical detec-
tion of a ZO-1, b occludin and c claudin-1 and its respective percent-
age of expression in colon at × 40. Data expressed as mean ± SEM 
(n = 4 per group) and statistical significance among groups evaluated 
by one-way ANOVA followed by Tukey’s test *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001 vs. DSS-control group
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barrier function by sealing the intracellular spaces between 
adjoining epithelial cells, consequently restricting the para-
cellular movement of harmful substances across intestinal 
mucosa [54]. Goblet cells and mucin production were also 
best protected by synbiotic and B. coagulans supplementa-
tions with GBRS alone also demonstrating a notable effect 
compared to that of the DSS-control (Fig. 4). A recent study 
[55] has demonstrated the ability of a Bacillus probiotic to 
upregulate the expression of TJ proteins in colitic mice, 
in line with these observations with B. coagulans supple-
mentation. In our previous study, B. coagulans spores in 
synbiotic combination with sugar cane fibre showed similar 
beneficial effects on the epithelial barrier function in DSS-
induced colitic mice [19]. While the efficacy of the synbiotic 
combination to stimulate TJ proteins and/or circumvent the 
TJ degradation by DSS needs further investigation, taken 
together the results support the ability of the prebiotic and 
probiotic combination to reinforce intestinal barrier integrity 
and help prevent the manifestation of IBD.
The breach of epithelial integrity in IBD also triggers 
aberrant inflammatory responses resulting in increased 
accumulation of pro-inflammatory mediators and thus 
further exacerbating the inflammation cascade and tissue 
damage [2]. B. coagulans alone, and in synbiotic combi-
nation, demonstrated excellent immunomodulatory and 
anti-inflammatory efficacy as evidenced by reduction in 
colonic pro-inflammatory cytokine levels of IL-1α, IL-1β, 
Il-6, IL-12, TNF-α, and IFN-γ in both PC and DC segments. 
The results were similar to our previous studies that demon-
strated marked immunomodulatory effects of B. coagulans 
MTCC 5856 spores in vitro with colonic cell cultures [14] 
and in vivo in mice colonic tissues [19]. Levels of IL-1β, 
IL-6 and TNF-α were reported to be elevated in IBD patients 
[56]. These cytokines are mainly secreted by activated 
lamina propria antigen-presenting cells (APC) in response 
to the inflammation. APCs are part of the mechanism that 
maintains intestinal immune tolerance in the steady state 
but also prevent inappropriate responses to components of 
the gut microbiota that contribute to pathology in IBD [57]. 
TNF-α plays a pivotal role in triggering the accumulation 
and activation of leukocytes in colitis and hence is an impor-
tant therapeutic target [58]. Blockade of IL-6 signalling with 
monoclonal antibodies was also reported to be effective in 
reducing chronic intestinal inflammation in a mouse model. 
This effect was associated with the activation of T cell apop-
tosis and the suppressed production of pro-inflammatory 
IFN-γ [59]. In contrast to a previous study [27] that used 
green dwarf banana flour and reported no effect on colonic 
cytokines, the current study with GBRS supplementation 
observed a noticeable reduction in levels of IL-1β, IL-6 and 
IFN-γ as well as the reduction in detected serum IL-12 lev-
els. However, the respective immune-regulatory effects were 
less pronounced compared to that with synbiotic supplemen-
tation. There was also no effect on levels of colonic IL-1α, 
IL-12, TNF-α and serum IL-10. Furthermore, in serum, 
synbiotic supplementation induced a marked reduction in 
pro-inflammatory IL-1β levels while concomitantly increas-
ing anti-inflammatory IL-10 indicating a synergistic effect.
Bacillus coagulans MTCC 5856 spores have been dem-
onstrated to impart strong immunomodulatory effects to 
colonic cells in vitro in an inflammatory state [14]. This 
observation highlights the potential for application of probi-
otics with substantial immunomodulatory capacity, in con-
junction with prebiotics with average immune-regulating 
effect, to potentiate combined anti-inflammatory effects to 
mitigate the aberrant immune responses in IBD. IL-10 plays 
a prominent role in counterbalancing Th1 and Th17 immune 
activity in IBD towards a Th2 response by downregulating 
antigen presentation and subsequent release of pro-inflam-
matory cytokines thereby attenuating mucosal inflammation 
[60]. IL-10 deficiency has been demonstrated to exacerbate 
colitis in the DSS-induced colitis model as IL-10−/− knock-
out mice develop spontaneous colitis [61]. Moreover, IL-10 
administration has been determined to ameliorate colitis in 
mice by suppressing intestinal inflammation and reducing 
pro-inflammatory cytokine production [62]. The anti-inflam-
matory potential of the synbiotic supplementation in the 
current study, therefore, warrants its application to human 
IBD trials to confirm the ability to regulate the exacerbated 
immune responses.
The supplementations also moderated other indicators of 
the inflammatory response. The B. coagulans and synbi-
otic supplementations suppressed increased colonic induc-
ible nitric oxide synthase (iNOS) activity. Th1 and Th17 
cytokines upregulate the iNOS expression and production 
nitric oxide (NO) in IBD that causes oxidative stress-related 
inflammation and tissue damage [63]. Elevated levels of 
CRP have been shown in human IBD [64]. When inflamma-
tion is triggered, circulating IL-6 (partly induced by IL-1β 
and TNF-α) stimulate the production of CRP in the liver and 
subsequent release into the bloodstream [65]. In the present 
study, the elicited levels of colonic IL-6 and serum CRP 
induced by DSS-induction were mitigated effectively by 
supplementations. Synbiotic, B. coagulans and GBRS sup-
plementations displayed potent immune regulating efficacies 
to normalise the elevated serum CRP levels indicative of 
Fig. 6  Effect of B. coagulans spores, GBRS and synbiotic on immune 
markers in colon tissues and blood serum. Protein levels of cytokines 
including a IL-1α, b IL-1β, c IL-6, d IL-12, e TNF-α, f IFN-γ in 
proximal and distal colon explants as well as cytokine levels of g 
IL-1β, h IL-10, and i IL-12 in blood serum were analysed by Bio-
plex. iNOS activity in colon tissues j measured by NOS activity assay 
and CRP levels in serum k by ELISA. Statistical significance among 
groups evaluated by one-way ANOVA followed by Tukey’s test. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. DSS-control 
group and data expressed as mean ± SEM (n = 3 per group)
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inflammation. Synbiotic was the most effective statistically 
(p < 0.0001) compared to the DSS-control (Fig. 6k). The 
combined immunomodulatory effect of B. coagulans and 
GBRS could, therefore, be accounted for by a potentiated 
synergistic efficacy of synbiotic supplementation in mitigat-
ing the pro-inflammatory cytokines. These findings indicate 
that the modulation of DSS-induced aberrant inflamma-
tory responses by components of synbiotic could be due to 
either a direct effect via suppression of pro-inflammatory 
cytokine or to an indirect effect imparted by maintenance 
of epithelial integrity. A boost to the epithelial barrier func-
tion would result in reduction of entry of foreign luminal 
antigens and thus lessen full activation of the innate immune 
system. There are therefore, multiple mechanisms by which 
the action of the synbiotic combination supplementation 
can address the underlying mechanisms that result in IBD 
pathology.
The synbiotic supplementation in the current study 
demonstrated strong ability to modulate faecal metabolic 
profile of DSS-induced mice compared with that of the 
DSS-control (Fig. 7). B. coagulans and GBRS supple-
mentations alone could not mediate the same modula-
tions in the metabolic profiles as observed by their syn-
biotic combination. Microbiota-derived metabolites and 
SCFAs, which are the signatures of the gut microbiota 
and modulate immune activity in the gut, are important 
indicators of dysbiotic patterns in IBD [66, 67]. However, 
the direct characterisation of the microbiome was not pos-
sible as DNA extracted from caecal, faecal and mucosal 
stool samples from DSS-induced mice in the present study, 
failed amplification before 16 s rRNA sequencing. This 
was due to the presence of DSS in the samples that is 
known to inhibit the PCR amplification [68]. Nevertheless, 
the profiling of microbiota-derived untargeted metabolites 
revealed distinct patterns between the DSS-control and the 
HC samples that are in agreement with previous reports 
[69, 70]. There was also a significant difference in faecal 
metabolic profiles from IBD subjects compared to that 
of their healthy counterparts. A similar trend in effects 
was observed in terms of SCFA profiles. SCFAs made in 
the colon are active metabolites that function to reduce 
inflammatory mediators and increasing epithelial barrier 
function [71]. The most abundant SCFAs in the colon are 
acetate, propionate and butyrate. These are produced by 
gut microbiota via fermentation of indigestible fibres. The 
concentrations of SCFAs vary along the length of the gut. 
The caecum and proximal colon show the highest levels 
that then decline towards distal colon segment [72]. More-
over, in the caecum and colon 95% of SCFAs are absorbed 
by the colonocytes while only 5% are excreted in the fae-
ces [73]. The synbiotic and GBRS supplementations elic-
ited elevated SCFA production along the entire length of 
colon. In contrast, B. coagulans alone was not very effec-
tive in inducing SCFAs along the colon past the caecum. 
Trachsel et al. [74] observed that resistant potato starch 
fed to pigs was initially fermented to high concentrations 
of lactate, especially in caecum by various lactic acid bac-
teria. This lactic acid was then metabolised into butyrate 
by the secondary fermenters such as Anaerostipes had-
rus, thus decreasing the level of lactate in faecal samples. 
The authors, therefore, projected the co-administration of 
resistant potato starch with the members of these bacterial 
Fig. 7  Effect of B. coagulans spores, GBRS and synbiotic on meta-
bolic modulations in DSS-induced colitic mice. a 2D-PLS-DA plot 
showing spatial division among groups that received different sup-
plementations, DSS-control mice that received no supplementation 
and HC. b Key compounds separating the groups are ranked based on 
variable importance projection (VIP) score plot from PLS-DA analy-
sis. BC B. coagulans, Syn synbiotic
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groups to enhance the beneficial effects. Similarly, in our 
previous study [19], B. coagulans spores combined with 
whole-plant sugar cane fibre, as a synergistic supplement 
to DSS-colitic mice, augmented the SCFAs levels along 
the entire colon length. It is inferred that, beyond the cae-
cum, fibre available for fermentation could be limited. 
The low DF (crude fibre + neutral detergent fibre) content 
in the standard rodent chow could be accounted for such 
effect. This conclusion is further supported by the abil-
ity of synbiotic and GBRS supplementation that showed 
higher levels of SCFAs production in mucosal-associated 
and faecal contents. GBRS treatment added 1.46 g more 
DF content (2 g/day/mouse) relative to unsupplemented 
standard chow (0.54 g/day/mice) in the GBRS and synbi-
otic supplemented chow diets. The similar levels of SCFA 
produced by both GBRS alone and synbiotic suggest there 
was only a limited role of the administered spore probiotic 
in mediating the greater SCFA levels. It is concluded that 
synergistically applying B. coagulans along with GBRS, 
could potentiate SCFAs production along the entire length 
of colon to mediate trophic beneficial effects in IBD. How-
ever, clinical trials would be needed to determine if the 
mouse results would also translate to the activity of the 
human gut microbiome.
Decreased SCFAs concentrations, particularly butyrate, 
have a direct effect on microbial perturbations. This results 
in defects in colonic barrier function and is associated 
with the related aberrant immune responses in IBD [18]. 
In vitro [75, 76] and in vivo [77] studies have determined 
the effectiveness of butyrate in increasing epithelial integ-
rity and mucus secretion. In the results of this study, the 
considerable increase in butyrate levels by synbiotic, 
GBRS and B. coagulans supplementation could also be 
related to the positive effects observed on the histology of 
the colon, barrier integrity and reduction in disease sever-
ity in DSS-induced mice. Butyrate is the preferred energy 
source for colonocytes and has the ability to regulate 
cytokines, thus showing protection against inflammation 
in UC and colorectal cancer [72]. The improved expres-
sion of TJ proteins and mucus staining in goblet cells 
observed here could be partially attributed to the elevated 
butyrate levels associated with synbiotic supplementation. 
Metabolites such as acetate and propionate, that were 
found to be elevated with synbiotic supplementation along 
the entire colonic length, have also been found to benefit 
epithelial integrity via binding with metabolite-sensing 
G-protein-coupled receptors such as GPR43, GPR109A, 
and modulating immune response [78–80]. Valerate has 
been determined to stimulate intestinal growth and attenu-
ate inflammatory pathogenesis in colitis [81]. This SCFA 
was also increased by synbiotic supplementation in this 
study. Therefore, a prebiotic component that directly or 
indirectly influences SCFA production capacity of a sym-
biotically administered probiotic and other beneficial gut 
microflora, is advantageous in modulating inflammation 
in IBD.
Conclusions
The research has highlighted a substantial efficacy of a syn-
biotic supplementation of GBRS with B. coagulans spores 
in reducing the clinical manifestations and severity of DSS-
induced colitis in a mouse model. The probiotic and prebi-
otic components complement each other to potentiate the 
beneficial effects. A substantial anti-inflammatory effect of 
the synbiotic supplementation was generated by suppress-
ing aberrant immune responses and colonic damage induced 
by DSS. The combination of the probiotic B. coagulans 
MTCC5856 spores and GBRS also improved the produc-
tion of the metabolites and SCFAs. Together these could 
similarly function to modulate the inflammatory parameters 
and ameliorate the disease severity.
The study provides valuable insights into synergistic 
mechanisms of synbiotic supplementation that operate by 
resolving dysregulated immune response, weakened mucosal 
barrier integrity and altered metabolic profile, thus attenuat-
ing gut inflammation. The observed synergistic function-
ing ameliorating or preventing the disease severity in DSS-
induced mice model supports its further investigation for 
mitigating inflammation in human IBD. Furthermore, syn-
ergistic combinations of these synbiotic ingredients could 
be applied to develop novel shelf-stable foods targeted at 
improving gut health.
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